1
|
Grégoire S, Moustié A, Lereaux G, Roussel-Berlier L, Hewitt N. Use of in vitro ADME methods to identify suitable analogs of homosalate and octisalate for use in a read-across safety assessment. J Appl Toxicol 2024; 44:1067-1083. [PMID: 38539266 DOI: 10.1002/jat.4603] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 03/07/2024] [Accepted: 03/09/2024] [Indexed: 07/21/2024]
Abstract
Case studies are needed to demonstrate the use of human-relevant New Approach Methodologies in cosmetics ingredient safety assessments. For read-across assessments, it is crucial to compare the target chemical with the most appropriate analog; therefore, reliable analog selection should consider physicochemical properties, bioavailability, metabolism, as well as the bioactivity of potential analogs. To complement in vitro bioactivity assays, we evaluated the suitability of three potential analogs for the UV filters, homosalate and octisalate, according to their in vitro ADME properties. We describe how technical aspects of conducting assays for these highly lipophilic chemicals were addressed and interpreted. There were several properties that were common to all five chemicals: they all had similar stability in gastrointestinal fluids (in which no hydrolysis to salicylic occurred); were not substrates of the P-glycoprotein efflux transporter; were highly protein bound; and were hydrolyzed to salicylic acid (which was also a major metabolite). The main properties differentiating the chemicals were their permeability in Caco-2 cells, plasma stability, clearance in hepatic models, and the extent of hydrolysis to salicylic acid. Cyclohexyl salicylate, octisalate, and homosalate were identified suitable analogs for each other, whereas butyloctyl salicylate exhibited ADME properties that were markedly different, indicating it is unsuitable. Isoamyl salicylate can be a suitable analog with interpretation for octisalate. In conclusion, in vitro ADME properties of five chemicals were measured and used to pair target and potential analogs. This study demonstrates the importance of robust ADME data for the selection of analogs in a read-across safety assessment.
Collapse
Affiliation(s)
| | - Anne Moustié
- L'Oréal Research & Innovation, Aulnay-sous Bois, France
| | | | | | | |
Collapse
|
2
|
Rej RK, Allu SR, Roy J, Acharyya RK, Kiran INC, Addepalli Y, Dhamodharan V. Orally Bioavailable Proteolysis-Targeting Chimeras: An Innovative Approach in the Golden Era of Discovering Small-Molecule Cancer Drugs. Pharmaceuticals (Basel) 2024; 17:494. [PMID: 38675453 PMCID: PMC11054475 DOI: 10.3390/ph17040494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Revised: 04/02/2024] [Accepted: 04/08/2024] [Indexed: 04/28/2024] Open
Abstract
Proteolysis-targeting chimeras (PROTACs) are an emerging therapeutic modality that show promise to open a target space not accessible to conventional small molecules via a degradation-based mechanism. PROTAC degraders, due to their bifunctional nature, which is categorized as 'beyond the Rule of Five', have gained attention as a distinctive therapeutic approach for oral administration in clinical settings. However, the development of PROTACs with adequate oral bioavailability remains a significant hurdle, largely due to their large size and less than ideal physical and chemical properties. This review encapsulates the latest advancements in orally delivered PROTACs that have entered clinical evaluation as well as developments highlighted in recent scholarly articles. The insights and methodologies elaborated upon in this review could be instrumental in supporting the discovery and refinement of novel PROTAC degraders aimed at the treatment of various human cancers.
Collapse
Affiliation(s)
- Rohan Kalyan Rej
- Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; (S.R.A.); (R.K.A.)
| | - Srinivasa Rao Allu
- Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; (S.R.A.); (R.K.A.)
| | - Joyeeta Roy
- Rogel Cancer Center, Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA;
| | - Ranjan Kumar Acharyya
- Rogel Cancer Center, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA; (S.R.A.); (R.K.A.)
| | - I. N. Chaithanya Kiran
- Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02139, USA;
| | - Yesu Addepalli
- Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA;
| | - V. Dhamodharan
- Institute of Organic Chemistry, Center for Nanosystems Chemistry, University of Wuerzburg, Am Hubland, 97074 Würzburg, Germany;
| |
Collapse
|
3
|
Cocetta V, Governa P, Borgonetti V, Tinazzi M, Peron G, Catanzaro D, Berretta M, Biagi M, Manetti F, Dall'Acqua S, Montopoli M. Cannabidiol Isolated From Cannabis sativa L. Protects Intestinal Barrier From In Vitro Inflammation and Oxidative Stress. Front Pharmacol 2021; 12:641210. [PMID: 33995048 PMCID: PMC8115937 DOI: 10.3389/fphar.2021.641210] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2020] [Accepted: 04/08/2021] [Indexed: 12/11/2022] Open
Abstract
The relevance and incidence of intestinal bowel diseases (IBD) have been increasing over the last 50 years and the current therapies are characterized by severe side effects, making essential the development of new strategies that combine efficacy and safety in the management of human IBD. Herbal products are highly considered in research aimed at discovering new approaches for IBD therapy and, among others, Cannabis sativa L. has been traditionally used for centuries as an analgesic and anti-inflammatory remedy also in different gastrointestinal disorders. This study aims to investigate the effects of different C. sativa isolated compounds in an in vitro model of intestinal epithelium. The ability of treatments to modulate markers of intestinal dysfunctions was tested on Caco-2 intestinal cell monolayers. Our results, obtained by evaluation of ROS production, TEER and paracellular permeability measurements and tight junctions evaluation show Cannabidiol as the most promising compound against intestinal inflammatory condition. Cannabidiol is able to inhibit ROS production and restore epithelial permeability during inflammatory and oxidative stress conditions, suggesting its possible application as adjuvant in IBD management.
Collapse
Affiliation(s)
- Veronica Cocetta
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy
| | - Paolo Governa
- Department of Biotechnology, Chemistry and Pharmacy Department of Excellence 2018-2022, University of Siena, Siena, Italy
| | - Vittoria Borgonetti
- Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), Section of Pharmacology, University of Florence, Florence, Italy
| | - Mattia Tinazzi
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy
| | - Gregorio Peron
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy
| | - Daniela Catanzaro
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy
| | - Massimiliano Berretta
- Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy
| | - Marco Biagi
- Department of Physical Sciences, Earth and Environment, University of Siena, Siena, Italy
| | - Fabrizio Manetti
- Department of Biotechnology, Chemistry and Pharmacy Department of Excellence 2018-2022, University of Siena, Siena, Italy
| | - Stefano Dall'Acqua
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy
| | - Monica Montopoli
- Department of Pharmaceutical Sciences, University of Padova, Padova, Italy.,Veneto Institute of Molecular Medicine, VIMM, Padova, Italy
| |
Collapse
|
4
|
Bhoopathy S, Bode C, Naageshwaran V, Weiskircher-Hildebrandt E, Mukkavilli V, Hidalgo IJ. Principles and Experimental Considerations for In Vitro Transporter Interaction Assays. Methods Mol Biol 2021; 2342:339-365. [PMID: 34272701 DOI: 10.1007/978-1-0716-1554-6_13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Drug transporters are universally acknowledged as important determinants of the absorption, distribution, metabolism, and excretion of both endogenous and exogenous compounds. Altered transporter function, whether due to genetic polymorphism, DDIs, disease, or environmental factors such as dietary constituents, can result in changes in drug efficacy and/or toxicity due to changes in circulating or tissue levels of either drugs or endogenous substrates.Prediction of whether and to what extent the biological fate of a drug is influenced by drug transporters, therefore, requires in vitro test systems that can accurately predict the risk and magnitude of clinical DDIs. While these in vitro assessments appear simple in theory, practitioners recognize that there are multiple factors that can influence experimental outcomes. A better understanding of these variables, including test compound characteristics, test systems, assay formats, and experimental design, will enable clear, actionable steps and translatable outcomes that may avoid unnecessary downstream clinical engagement. This chapter will delineate the role of these variables in improving in vitro assay outcomes.
Collapse
|
5
|
Pike A, Williamson B, Harlfinger S, Martin S, McGinnity DF. Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective. Drug Discov Today 2020; 25:1793-1800. [DOI: 10.1016/j.drudis.2020.07.013] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2020] [Revised: 07/07/2020] [Accepted: 07/14/2020] [Indexed: 12/28/2022]
|
6
|
Carullo G, Governa P, Spizzirri UG, Biagi M, Sciubba F, Giorgi G, Loizzo MR, Di Cocco ME, Aiello F, Restuccia D. Sangiovese cv Pomace Seeds Extract-Fortified Kefir Exerts Anti-Inflammatory Activity in an In Vitro Model of Intestinal Epithelium Using Caco-2 Cells. Antioxidants (Basel) 2020; 9:E54. [PMID: 31936207 PMCID: PMC7022605 DOI: 10.3390/antiox9010054] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2019] [Revised: 01/04/2020] [Accepted: 01/05/2020] [Indexed: 02/06/2023] Open
Abstract
Inflammatory bowel disease and food allergies are a growing topic in the field of nutrition science. Polyphenols, which are the most important secondary metabolites of plants, demonstrated to modulate the expression and/or production of numerous proteins, but also to regulate the intestinal ecosystem. In this context, our aim was the investigation of protective effects against the gastrointestinal mucosa of fortified milk kefir obtained by adding seeds extract from Sangiovese cv. Pomace. Methods: An ultrasound-assisted method was used to obtain the extracts. All the extracts were assayed for the antioxidant activity. The best extract was used as an additive of fermented milk kefir to obtain a fortified final product. Kefir samples were analyzed by NMR spectroscopy. The efficiency of the barrier functions was evaluated by measuring trans-epithelial electric resistance (TEER) using a voltmeter. Results: the enriched kefir (Ksgn) possesses higher antioxidant performances compared to the unfortified sample (Kwht). Kwht and Ksgn did not alter Caco-2 TEER in basal condition.
Collapse
Affiliation(s)
- Gabriele Carullo
- Dipartimento di Farmacia e Scienze della Salute e della Nutrizione—Dipartimento di Eccellenza 2018-2022, Università della Calabria, Edificio Polifunzionale, 87036 Rende (CS), Italy; (G.C.); (U.G.S.); (M.R.L.); (D.R.)
| | - Paolo Governa
- Dipartimento di Biotecnologie, Chimica e Farmacia—Dipartimento di Eccellenza 2018-2022, Università di Siena, Via Aldo Moro 2, 53100 Siena, Italy; (P.G.); (G.G.)
| | - Umile Gianfranco Spizzirri
- Dipartimento di Farmacia e Scienze della Salute e della Nutrizione—Dipartimento di Eccellenza 2018-2022, Università della Calabria, Edificio Polifunzionale, 87036 Rende (CS), Italy; (G.C.); (U.G.S.); (M.R.L.); (D.R.)
| | - Marco Biagi
- Dipartimento di Scienze Fisiche, della Terra e dell’Ambiente, Università di Siena, Via Laterina 8, 53100 Siena, Italy;
| | - Fabio Sciubba
- Dipartimento di Chimica, Università di Roma “La Sapienza”, Piazzale Aldo Moro 5, 00185 Roma, Italy; (F.S.); (M.E.D.C.)
| | - Gianluca Giorgi
- Dipartimento di Biotecnologie, Chimica e Farmacia—Dipartimento di Eccellenza 2018-2022, Università di Siena, Via Aldo Moro 2, 53100 Siena, Italy; (P.G.); (G.G.)
| | - Monica Rosa Loizzo
- Dipartimento di Farmacia e Scienze della Salute e della Nutrizione—Dipartimento di Eccellenza 2018-2022, Università della Calabria, Edificio Polifunzionale, 87036 Rende (CS), Italy; (G.C.); (U.G.S.); (M.R.L.); (D.R.)
| | - Maria Enrica Di Cocco
- Dipartimento di Chimica, Università di Roma “La Sapienza”, Piazzale Aldo Moro 5, 00185 Roma, Italy; (F.S.); (M.E.D.C.)
| | - Francesca Aiello
- Dipartimento di Farmacia e Scienze della Salute e della Nutrizione—Dipartimento di Eccellenza 2018-2022, Università della Calabria, Edificio Polifunzionale, 87036 Rende (CS), Italy; (G.C.); (U.G.S.); (M.R.L.); (D.R.)
| | - Donatella Restuccia
- Dipartimento di Farmacia e Scienze della Salute e della Nutrizione—Dipartimento di Eccellenza 2018-2022, Università della Calabria, Edificio Polifunzionale, 87036 Rende (CS), Italy; (G.C.); (U.G.S.); (M.R.L.); (D.R.)
| |
Collapse
|
7
|
Cai X, Madari S, Walker A, Paiva A, Li Y, Herbst J, Shou W, Weller H. Addition of Optimized Bovine Serum Albumin Level in a High-Throughput Caco-2 Assay Enabled Accurate Permeability Assessment for Lipophilic Compounds. SLAS DISCOVERY 2019; 24:738-744. [DOI: 10.1177/2472555219848483] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The Caco-2 permeability assay is a well-accepted in vitro model to evaluate compounds’ potential for oral absorption at early discovery. However, for many lipophilic compounds, no meaningful Caco-2 data could be generated due to their low solubility in assay buffer and/or poor recovery from the assay. In our previous study, we reported an organic catch approach to improve compound recovery. To further reduce compound loss and increase solubility in aqueous buffer, we explored the addition of bovine serum albumin (BSA). However, in contrast to the commonly used BSA level at 4%, a lower level of BSA was selected in an effort to minimize the potential risk of missing the identification of efflux substrates, and to avoid the extensive sample cleanup needed for 4% BSA. Through a systematic evaluation, it was found that 0.5% BSA was effective in enhancing compound solubility and reducing nonspecific binding, which allowed reliable assessment of the permeability and efflux potential for lipophilic compounds. Also, with an optimized sample handling process, no extra sample cleanup was required before liquid chromatography–mass spectrometry (LC-MS) analysis. The implementation of this assay has enabled accurate permeability assessment for compounds that had poor solubility and/or poor mass balance under the non-BSA assay conditions.
Collapse
Affiliation(s)
- Xianmei Cai
- Synthesis and Analytical Technology Team, Bristol-Myers Squibb, Hopewell, NJ, USA
| | - Shilpa Madari
- Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
- Department of Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim, Ridgefield, CT, USA
| | - Aaron Walker
- Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | - Anthony Paiva
- Synthesis and Analytical Technology Team, Bristol-Myers Squibb, Hopewell, NJ, USA
| | - Ying Li
- Synthesis and Analytical Technology Team, Bristol-Myers Squibb, Hopewell, NJ, USA
| | - John Herbst
- Lead Discovery & Optimization, Bristol-Myers Squibb, Wallingford, CT, USA
| | - Wilson Shou
- Synthesis and Analytical Technology Team, Bristol-Myers Squibb, Hopewell, NJ, USA
| | - Harold Weller
- Synthesis and Analytical Technology Team, Bristol-Myers Squibb, Hopewell, NJ, USA
| |
Collapse
|
8
|
Governa P, Marchi M, Cocetta V, De Leo B, Saunders PTK, Catanzaro D, Miraldi E, Montopoli M, Biagi M. Effects of Boswellia Serrata Roxb. and Curcuma longa L. in an In Vitro Intestinal Inflammation Model Using Immune Cells and Caco-2. Pharmaceuticals (Basel) 2018; 11:ph11040126. [PMID: 30463367 PMCID: PMC6316569 DOI: 10.3390/ph11040126] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 11/14/2018] [Accepted: 11/16/2018] [Indexed: 12/22/2022] Open
Abstract
Inflammatory bowel diseases, which consist of chronic inflammatory conditions of the colon and the small intestine, are considered a global disease of our modern society. Recently, the interest toward the use of herbal therapies for the management of inflammatory bowel diseases has increased because of their effectiveness and favourable safety profile, compared to conventional drugs. Boswellia serrata Roxb. and Curcuma longa L. are amongst the most promising herbal drugs, however, their clinical use in inflammatory bowel diseases is limited and little is known on their mechanism of action. The aim of this work was to investigate the effects of two phytochemically characterized extracts of B. serrata and C. longa in an in vitro model of intestinal inflammation. Their impact on cytokine release and reactive oxygen species production, as well as the maintenance of the intestinal barrier function and on intestinal mucosa immune cells infiltration, has been evaluated. The extracts showed a good protective effect on the intestinal epithelium at 1 µg/mL, with TEER values increasing by approximately 1.5 fold, compared to LPS-stimulated cells. C. longa showed an anti-inflammatory mechanism of action, reducing IL-8, TNF-α and IL-6 production by approximately 30%, 25% and 40%, respectively, compared to the inflammatory stimuli. B. serrata action was linked to its antioxidant effect, with ROS production being reduced by 25%, compared to H2O2-stimulated Caco-2 cells. C. longa and B. serrata resulted to be promising agents for the management of inflammatory bowel diseases by modulating in vitro parameters which have been identified in the clinical conditions.
Collapse
Affiliation(s)
- Paolo Governa
- Department of Physical Sciences, Hearth and Environment, University of Siena, Via Laterina 8, 53100 Siena, Italy.
- Department of Biotechnology, Chemistry and Pharmacy⁻Department of Excellence 2018⁻2022, University of Siena, Via Aldo Moro 2, 53100 Siena, Italy.
| | - Maddalena Marchi
- Department of Physical Sciences, Hearth and Environment, University of Siena, Via Laterina 8, 53100 Siena, Italy.
| | - Veronica Cocetta
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo Egidio Meneghetti 2, 35131 Padua, Italy.
| | - Bianca De Leo
- MRC Centres for Inflammation Research and Reproductive Health, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
| | - Philippa T K Saunders
- MRC Centre for Inflammation Research, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
| | - Daniela Catanzaro
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo Egidio Meneghetti 2, 35131 Padua, Italy.
| | - Elisabetta Miraldi
- Department of Physical Sciences, Hearth and Environment, University of Siena, Via Laterina 8, 53100 Siena, Italy.
| | - Monica Montopoli
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo Egidio Meneghetti 2, 35131 Padua, Italy.
- Venetian Institute of Molecular Medicine, Via Orus 2, 35129 Padua, Italy.
| | - Marco Biagi
- Department of Physical Sciences, Hearth and Environment, University of Siena, Via Laterina 8, 53100 Siena, Italy.
| |
Collapse
|
9
|
Katneni K, Pham T, Saunders J, Chen G, Patil R, White KL, Abla N, Chiu FCK, Shackleford DM, Charman SA. Using Human Plasma as an Assay Medium in Caco-2 Studies Improves Mass Balance for Lipophilic Compounds. Pharm Res 2018; 35:210. [PMID: 30225649 PMCID: PMC6156755 DOI: 10.1007/s11095-018-2493-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2018] [Accepted: 09/04/2018] [Indexed: 11/30/2022]
Abstract
PURPOSE To examine the utility of human plasma as an assay medium in Caco-2 permeability studies to overcome poor mass balance and inadequate sink conditions frequently encountered with lipophilic compounds. METHODS Caco-2 permeability was assessed for reference compounds with known transport mechanisms using either pH 7.4 buffer or human plasma as the assay medium in both the apical and basolateral chambers. When using plasma, Papp values were corrected for the unbound fraction in the donor chamber. The utility of the approach was assessed by measuring the permeability of selected antimalarial compounds using the two assay media. RESULTS Caco-2 cell monolayer integrity and P-gp transporter function were unaffected by the presence of human plasma in the donor and acceptor chambers. For many of the reference compounds having good mass balance with buffer as the medium, higher Papp values were observed with plasma, likely due to improved acceptor sink conditions. The lipophilic antimalarial compounds exhibited low mass balance with buffer, however the use of plasma markedly improved mass balance allowing the determination of more reliable Papp values. CONCLUSIONS The results support the utility of human plasma as an alternate Caco-2 assay medium to improve mass balance and permeability measurements for lipophilic compounds.
Collapse
Affiliation(s)
- Kasiram Katneni
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Thao Pham
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Jessica Saunders
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Gong Chen
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Rahul Patil
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Karen L White
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - Nada Abla
- Medicines for Malaria Venture, 20, Route de Pré-Bois, 1215, Geneva 15, Switzerland
| | - Francis C K Chiu
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia
| | - David M Shackleford
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia.
| | - Susan A Charman
- Centre for Drug Candidate Optimisation, Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville, VIC, 3052, Australia.
| |
Collapse
|
10
|
Küblbeck J, Hakkarainen JJ, Petsalo A, Vellonen KS, Tolonen A, Reponen P, Forsberg MM, Honkakoski P. Genetically Modified Caco-2 Cells With Improved Cytochrome P450 Metabolic Capacity. J Pharm Sci 2016; 105:941-949. [DOI: 10.1016/s0022-3549(15)00187-2] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2015] [Revised: 10/24/2015] [Accepted: 11/03/2015] [Indexed: 10/22/2022]
|
11
|
Bhoopathy S, Bode C, Naageshwaran V, Weiskircher-Hildebrandt EA, Hidalgo IJ. Principles and experimental considerations for in vitro transporter interaction assays. Methods Mol Biol 2014; 1113:229-252. [PMID: 24523116 DOI: 10.1007/978-1-62703-758-7_12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
Drug transporters are now universally acknowledged as important determinants of the absorption, distribution, metabolism and excretion of both endogenous and exogenous compounds. Altered transporter function, whether due to genetic polymorphism, DDIs, disease, or environmental factors such as dietary constituents, can result in changes in drug efficacy and/or toxicity due to changes in circulating or tissue levels of either drugs or endogenous substrates.Prediction of whether and to what extent the biological fate of a drug is influenced by drug transporters, therefore, requires in vitro test systems that can accurately predict the risk and magnitude of clinical DDIs. While these in vitro assessments appear simple in theory, practitioners recognize that there are multiple factors that can influence experimental outcomes. A better understanding of these variables, including test compound characteristics, test systems, assay formats, and experimental design will enable clear, actionable steps and translatable outcomes that may avoid unnecessary downstream clinical engagement. This chapter will delineate the role of these variables in improving in vitro assay outcomes.
Collapse
Affiliation(s)
- Sid Bhoopathy
- Absorption Systems LP, 436 Creamery Way, Suite 600, Exton, PA, USA
| | | | | | | | | |
Collapse
|
12
|
Zhang Y, Hu Y, Feng Y, Kodithuwakku ND, Fang W, Li Y, Huang W. The inhibitory and combinative mechanism of HZ08 with P-glycoprotein expressed on the membrane of Caco-2 cell line. Toxicol Appl Pharmacol 2014; 274:232-9. [DOI: 10.1016/j.taap.2013.11.019] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Revised: 10/29/2013] [Accepted: 11/23/2013] [Indexed: 01/15/2023]
|
13
|
The Caco-2 cell culture model enables sensitive detection of enhanced protein permeability in the presence of N-decyl-β-d-maltopyranoside. N Biotechnol 2013; 30:507-15. [DOI: 10.1016/j.nbt.2013.05.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2013] [Revised: 04/16/2013] [Accepted: 05/20/2013] [Indexed: 11/18/2022]
|
14
|
Broeders JJW, van Eijkeren JCH, Blaauboer BJ, Hermens JLM. Transport of Chlorpromazine in the Caco-2 Cell Permeability Assay: A Kinetic Study. Chem Res Toxicol 2012; 25:1442-51. [DOI: 10.1021/tx300221k] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Jessica J. W. Broeders
- Institute for Risk Assessment
Sciences (IRAS), Utrecht University, P.O.
Box 80.177, NL-3508 TD Utrecht, The Netherlands
| | - Jan C. H. van Eijkeren
- National Institute of Public Health and the Environment (RIVM), P.O. Box
1, NL-3720 BA Bilthoven, The Netherlands
| | - Bas J. Blaauboer
- Institute for Risk Assessment
Sciences (IRAS), Utrecht University, P.O.
Box 80.177, NL-3508 TD Utrecht, The Netherlands
| | - Joop L. M. Hermens
- Institute for Risk Assessment
Sciences (IRAS), Utrecht University, P.O.
Box 80.177, NL-3508 TD Utrecht, The Netherlands
| |
Collapse
|